AtriCure, Inc. (ATRC) |
50.43 -0.12 (-0.24%)
|
08-19 00:35 |
Open: |
50.25 |
Pre. Close: |
50.55 |
High:
|
50.87 |
Low:
|
49.51 |
Volume:
|
171,123 |
Market Cap:
|
2,341(M) |
|
|
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
52.5 - 52.86 |
52.86 - 53.15 |
Low:
|
49.3 - 49.63 |
49.63 - 49.91 |
Close:
|
50.06 - 50.6 |
50.6 - 51.06 |
|
Technical analysis |
as of: 2022-08-18 3:50:55 PM |
Overall:
|
|
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
Target: |
Six months: 61.85 One year: 72.24 |
Support: |
Support1: 46.46 Support2: 42.45  |
Resistance: |
Resistance1: 52.95 Resistance2: 61.85 |
Pivot: |
50.5  |
Moving Average: |
MA(5): 51.68 MA(20): 49.52 
MA(100): 47.24 MA(250): 60.73  |
MACD: |
MACD(12,26): 1.9 Signal(9): 2  |
Stochastic oscillator: |
%K(14,3): 73.9 %D(3): 84.1  |
RSI: |
RSI(14): 58.4  |
52-week: |
High: 89.18 Low: 32.84 |
Average Vol(K): |
3-Month: 259 (K) 10-Days: 192 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATRC ] has closed below upper band by 46.3%. Bollinger Bands are 48.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
Headline News |
Wed, 17 Aug 2022 Is it Time to Dump AtriCure Inc. (ATRC) Stock After it Is Lower By 0.96% in a Week? - InvestorsObserver
Wed, 17 Aug 2022 Noteworthy Wednesday Option Activity: SAVA, ATRC, SQ - Nasdaq
Wed, 17 Aug 2022 AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Lowered by Victory Capital Management Inc. - Defense World
Tue, 16 Aug 2022 Qube Research & Technologies Ltd Has $1.41 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Sun, 14 Aug 2022 Envestnet Asset Management Inc. Sells 649 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Mon, 08 Aug 2022 Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments - Yahoo Finance
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Medical Instruments & Supplies |
Shares Out. |
46 (M) |
Shares Float |
45 (M) |
% Held by Insiders
|
2.8 (%) |
% Held by Institutions
|
101.5 (%) |
Shares Short
|
1,820 (K) |
Shares Short P.Month
|
1,900 (K) |
Stock Financials |
EPS
|
1.12 |
EPS Est Next Qtl
|
-0.19 |
EPS Est This Year
|
-0.95 |
EPS Est Next Year
|
-0.71 |
Book Value (p.s.)
|
9.84 |
Profit Margin (%)
|
17.6 |
Operating Margin (%)
|
-16.1 |
Return on Assets (ttm)
|
-4.7 |
Return on Equity (ttm)
|
12.6 |
Qtrly Rev. Growth
|
18.3 |
Gross Profit (p.s.)
|
4.43 |
Sales Per Share
|
6.52 |
EBITDA (p.s.)
|
-0.8 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-20 (M) |
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
PE Ratio
|
44.85 |
PEG Ratio
|
-2.3 |
Price to Book value
|
5.15 |
Price to Sales
|
7.77 |
Price to Cash Flow
|
-115.74 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|